IMMUNOPOTENTIATING COMPOUNDS

US 20090232844A1
Filed: 03/23/2007
Published: 09/17/2009
Est. Priority Date: 03/23/2006
Status: Active Grant

First Claim

Patent Images

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer, wherein;

R¹and R²are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl, —

C(═

O)NR⁷R⁸, —

C(═

O)R⁹, —

C(═

O)OR⁹, —

S(═

O)_qR¹⁰, C_6-10aryl-C_1-6alkyl, C_6-10aryloxy-C_1-6alkyl, —

(CH₂)_mCH═

CH(CH₂)_nR⁶, and —

(CH₂)_mC≡

C(CH₂)_nR⁶, wherein each of the C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl is optionally substituted by up to 10 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═

O)R^b, C(═

O)NR^cR^d, C(═

O)OR^a, C(═

S)NR^cR^a, OC(═

O)R^b, OC(═

O)NR^cR^d, NR^cR^d, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^b, and S(═

O)₂NR^cR^d;

or R¹and R²together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═

O)R^b, C(═

O)NR^cR^d, C(═

O)OR^a, C(═

S)NR^cR^d, OC(═

O)R^b, OC(═

O)NR^cR^d, NR^cR^d, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^b, and S(═

O)₂NR^cR^d;

R³is H, C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl, —

(CH₂)_mCH═

CH(CH₂)_nR⁶, —

(CH₂)_mC≡

C(CH₂)_nR⁶, —

C(═

O)NR⁷R⁸, —

C(═

O)R⁹, —

C(═

O)OR⁹, or —

S(═

O)_qR¹⁰, wherein each of the C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═

O)R^b, C(═

O)NR^cR^d, C(═

O)OR^a, C(═

S)NR^cR^d, OC(═

O)R^b, OC(═

O)NR^cR^d, NR^cR^d, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^d, and S(═

O)₂NR^cR^d;

R⁴and R⁵are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy, halogen, trihalomethyl, —

NR⁷R⁸, —

OR⁹, —

C(═

O)R⁹, —

C(═

O)OR⁹, —

C(═

O)NR⁷R⁸, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^b, and S(═

O)₂NR^cR^dwherein the C_1-6alkyl or C_1-6alkoxy is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═

O)R^b, C(═

O)NR^cR^d, C(═

O)OR^a, C(═

S)NR^cR^d, OC(═

O)R^b, OC(═

O)NR^cR^d, NR^cR^d, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^d, and S(═

O)₂NR^cR^d;

or R⁴and R⁵together with the two carbon atoms to which they are attached form a 5-7 membered cycloalkyl, a 5-7 membered heterocycloalkyl, or a 5-7 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4 or 5 R¹²;

each R⁶is independently H, halo, C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C(═

O)OH, or C(═

O)O—

(C_1-6alkyl), wherein each of the C_1-6alkyl, C_2-6alkenyl and C_6-10aryl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═

O)R^b′, C(═

O)NR^c′R^d′, C(═

O)OR^a′, C(═

S)NR^c′R^d′, OC(═

O)R^b′, OC(═

O)NR^c′R^d′, NR^c′R^d′, NR^cC(═

O)R^b′, NR^c′C(═

O)OR^a′, NR^c′S(═

O)₂R^b′, S(═

O)R^b′, S(═

O)NR^c′R^d′, S(═

O)₂OH, S(═

O)₂R^b′, and S(═

O)₂NR^c′R^d′;

R⁷and R⁸are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl, C_6-10aryloxy-C_1-6alkyl, —

(CH₂)_mCH═

CH(CH₂)_nR¹¹, and —

(CH₂)_mC≡

C(CH₂)_nR¹¹, wherein each of the C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl is optionally substituted by up to 10 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a′, C(═

O)R^b′, C(═

O)NR^c′R^d′, C(═

O)OR^a′, C(═

S)NR^c′R^d′, OC(═

O)R^b′, OC(═

O)NR^c′R^d′, NR^c′R^d′, NR^cC(═

O)R^b′, NR^c′C(═

O)OR^a′, NR^c′S(═

O)₂R^b′, S(═

O)R^b′, S(═

O)NR^c′R^d′, S(═

O)₂OH, S(═

O)₂R^b′, and S(═

O)₂NR^c′R^d′;

or R⁷and R⁸together with the N atom to which they are attached form a heterocyclyl group optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═

O)R^b′, C(═

O)NR^c′R^d′, C(═

O)OR^a′, C(═

S)NR^c′R^d′, OC(═

O)R^b′, OC(═

O)NR^c′R^d′, NR^c′R^d′, NR^cC(═

O)R^b′, NR^cC(═

O)OR^a′, NR^c′S(═

O)₂R^b′, S(═

O)R^b′, S(═

O)NR^c′R^d′, S(═

O)₂OH, S(═

O)₂R^b′, and S(═

O)₂NR^c′R^d′;

each R⁹is independently H, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, or C_1-6alkyl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═

O)R^b′, C(═

O)NR^c′R^d′, C(═

O)OR^a′, C(═

S)NR^c′R^d′, OC(═

O)R^b′, OC(═

O)NR^c′R^d′, NR^c′R^d′, NR^cC(═

O)R^d′, NR^c′C(═

O)OR^a′, NR^c′S(═

O)₂R^b′, S(═

O)R^b′, S(═

O)NR^c′R^d′, S(═

O)₂OH, S(═

O)₂R^b′, and S(═

O)₂NR^c′R^d′;

each R¹⁰is independently C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, trihalomethyl, or —

NR⁷R⁸, wherein each of the C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, and C_6-10aryl-C_1-6alkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═

O)R^b′, C(═

O)NR^c′R^d′, C(═

O)OR^a′, C(═

S)NR^c′R^d′, OC(═

O)R^b′, OC(═

O)NR^c′R^d′, NR^c′R^d′, NR^cC(═

O)R^b′, NR^c′C(═

O)OR^a′, NR^c′S(═

O)₂R^b′, S(═

O)R^b′, S(═

O)NR^c′R^d′S(═

O)₂OH, S(O)₂R^b′, and S(═

O)₂NR^c′R^d′;

each R¹¹is independently H, halo, C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C(═

O)OH, or C(═

O)O—

(C_1-6alkyl), wherein each of the C_1-6alkyl, C_2-6alkenyl and C_6-10aryl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a″, SR^a″, C(═

O)R^b″, C(═

O)NR^c″R^d″, C(═

O)OR^a″, C(═

S)NR^c″R^d″, OC(═

O)R^b″, OC(═

O)NR^c″R^d″, NR^c″R^d″, NR^c″C(O)R^b″, NR^c″C(═

O)OR^a″, NR^c″S(═

O)₂R^b″, S(═

O)R^b″, S(═

O)NR^c″R^d″, S(═

O)₂OH, S(═

O)₂R^b″, and S(═

O)₂NR^c″R^d″;

each R¹²is independently C_1-6alkyl, C_1-6alkoxy, halogen, trihalomethyl, —

NR⁷R⁸, —

OR⁹, —

C(═

O)R⁹, —

C(═

O)OR⁹, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^b, and S(═

O)₂NR^cR^d, or —

C(═

O)NR⁷R⁸, wherein the C_1-6alkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═

O)R^b, C(═

O)NR^cR^d, C(═

O)OR^a, C(═

S)NR^cR^d, OC(═

O)R^b, OC(═

O)NR^cR^d, NR^cR^d, NR^cC(═

O)R^b, NR^cC(═

O)OR^a, NR^cS(═

O)₂R^b, S(═

O)R^b, S(═

O)NR^cR^d, S(═

O)₂OH, S(═

O)₂R^b, and S(═

O)₂NR^cR^d;

R^a, R^a′ and R^a″ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocycloalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;

R^b, R^b′ and R^b′ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;

R^cand R^dare each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;

or R^cand R^dtogether with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^c′ and R^d′ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;

or R^c′ and R^d′ together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^c″ and R^d″ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;

or R^c″ and R^d″ together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

m and n are each, independently, selected from 0, 1, 2 and 3; and

each q is independently 0, 1 or 2.

View all claims

2 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).

Citations

115 Claims

1. A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer, wherein;
  
  R¹and R²are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl, —
  
  C(═
  
  O)NR⁷R⁸, —
  
  C(═
  
  O)R⁹, —
  
  C(═
  
  O)OR⁹, —
  
  S(═
  
  O)_qR¹⁰, C_6-10aryl-C_1-6alkyl, C_6-10aryloxy-C_1-6alkyl, —
  
  (CH₂)_mCH═
  
  CH(CH₂)_nR⁶, and —
  
  (CH₂)_mC≡
  
  C(CH₂)_nR⁶, wherein each of the C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl is optionally substituted by up to 10 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═
  
  O)R^b, C(═
  
  O)NR^cR^d, C(═
  
  O)OR^a, C(═
  
  S)NR^cR^a, OC(═
  
  O)R^b, OC(═
  
  O)NR^cR^d, NR^cR^d, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^b, and S(═
  
  O)₂NR^cR^d;
  
  or R¹and R²together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═
  
  O)R^b, C(═
  
  O)NR^cR^d, C(═
  
  O)OR^a, C(═
  
  S)NR^cR^d, OC(═
  
  O)R^b, OC(═
  
  O)NR^cR^d, NR^cR^d, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^b, and S(═
  
  O)₂NR^cR^d;
  
  R³is H, C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl, —
  
  (CH₂)_mCH═
  
  CH(CH₂)_nR⁶, —
  
  (CH₂)_mC≡
  
  C(CH₂)_nR⁶, —
  
  C(═
  
  O)NR⁷R⁸, —
  
  C(═
  
  O)R⁹, —
  
  C(═
  
  O)OR⁹, or —
  
  S(═
  
  O)_qR¹⁰, wherein each of the C_1-6alkyl, C_6-10aryl, heterocyclyl, C_3-14cycloalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═
  
  O)R^b, C(═
  
  O)NR^cR^d, C(═
  
  O)OR^a, C(═
  
  S)NR^cR^d, OC(═
  
  O)R^b, OC(═
  
  O)NR^cR^d, NR^cR^d, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^d, and S(═
  
  O)₂NR^cR^d;
  
  R⁴and R⁵are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy, halogen, trihalomethyl, —
  
  NR⁷R⁸, —
  
  OR⁹, —
  
  C(═
  
  O)R⁹, —
  
  C(═
  
  O)OR⁹, —
  
  C(═
  
  O)NR⁷R⁸, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^b, and S(═
  
  O)₂NR^cR^dwherein the C_1-6alkyl or C_1-6alkoxy is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═
  
  O)R^b, C(═
  
  O)NR^cR^d, C(═
  
  O)OR^a, C(═
  
  S)NR^cR^d, OC(═
  
  O)R^b, OC(═
  
  O)NR^cR^d, NR^cR^d, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^d, and S(═
  
  O)₂NR^cR^d;
  
  or R⁴and R⁵together with the two carbon atoms to which they are attached form a 5-7 membered cycloalkyl, a 5-7 membered heterocycloalkyl, or a 5-7 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4 or 5 R¹²;
  
  each R⁶is independently H, halo, C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C(═
  
  O)OH, or C(═
  
  O)O—
  
  (C_1-6alkyl), wherein each of the C_1-6alkyl, C_2-6alkenyl and C_6-10aryl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═
  
  O)R^b′, C(═
  
  O)NR^c′R^d′, C(═
  
  O)OR^a′, C(═
  
  S)NR^c′R^d′, OC(═
  
  O)R^b′, OC(═
  
  O)NR^c′R^d′, NR^c′R^d′, NR^cC(═
  
  O)R^b′, NR^c′C(═
  
  O)OR^a′, NR^c′S(═
  
  O)₂R^b′, S(═
  
  O)R^b′, S(═
  
  O)NR^c′R^d′, S(═
  
  O)₂OH, S(═
  
  O)₂R^b′, and S(═
  
  O)₂NR^c′R^d′;
  
  R⁷and R⁸are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl, C_6-10aryloxy-C_1-6alkyl, —
  
  (CH₂)_mCH═
  
  CH(CH₂)_nR¹¹, and —
  
  (CH₂)_mC≡
  
  C(CH₂)_nR¹¹, wherein each of the C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl is optionally substituted by up to 10 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a′, C(═
  
  O)R^b′, C(═
  
  O)NR^c′R^d′, C(═
  
  O)OR^a′, C(═
  
  S)NR^c′R^d′, OC(═
  
  O)R^b′, OC(═
  
  O)NR^c′R^d′, NR^c′R^d′, NR^cC(═
  
  O)R^b′, NR^c′C(═
  
  O)OR^a′, NR^c′S(═
  
  O)₂R^b′, S(═
  
  O)R^b′, S(═
  
  O)NR^c′R^d′, S(═
  
  O)₂OH, S(═
  
  O)₂R^b′, and S(═
  
  O)₂NR^c′R^d′;
  
  or R⁷and R⁸together with the N atom to which they are attached form a heterocyclyl group optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═
  
  O)R^b′, C(═
  
  O)NR^c′R^d′, C(═
  
  O)OR^a′, C(═
  
  S)NR^c′R^d′, OC(═
  
  O)R^b′, OC(═
  
  O)NR^c′R^d′, NR^c′R^d′, NR^cC(═
  
  O)R^b′, NR^cC(═
  
  O)OR^a′, NR^c′S(═
  
  O)₂R^b′, S(═
  
  O)R^b′, S(═
  
  O)NR^c′R^d′, S(═
  
  O)₂OH, S(═
  
  O)₂R^b′, and S(═
  
  O)₂NR^c′R^d′;
  
  each R⁹is independently H, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, or C_1-6alkyl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═
  
  O)R^b′, C(═
  
  O)NR^c′R^d′, C(═
  
  O)OR^a′, C(═
  
  S)NR^c′R^d′, OC(═
  
  O)R^b′, OC(═
  
  O)NR^c′R^d′, NR^c′R^d′, NR^cC(═
  
  O)R^d′, NR^c′C(═
  
  O)OR^a′, NR^c′S(═
  
  O)₂R^b′, S(═
  
  O)R^b′, S(═
  
  O)NR^c′R^d′, S(═
  
  O)₂OH, S(═
  
  O)₂R^b′, and S(═
  
  O)₂NR^c′R^d′;
  
  each R¹⁰is independently C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, trihalomethyl, or —
  
  NR⁷R⁸, wherein each of the C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, and C_6-10aryl-C_1-6alkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a′, SR^a′, C(═
  
  O)R^b′, C(═
  
  O)NR^c′R^d′, C(═
  
  O)OR^a′, C(═
  
  S)NR^c′R^d′, OC(═
  
  O)R^b′, OC(═
  
  O)NR^c′R^d′, NR^c′R^d′, NR^cC(═
  
  O)R^b′, NR^c′C(═
  
  O)OR^a′, NR^c′S(═
  
  O)₂R^b′, S(═
  
  O)R^b′, S(═
  
  O)NR^c′R^d′S(═
  
  O)₂OH, S(O)₂R^b′, and S(═
  
  O)₂NR^c′R^d′;
  
  each R¹¹is independently H, halo, C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, C(═
  
  O)OH, or C(═
  
  O)O—
  
  (C_1-6alkyl), wherein each of the C_1-6alkyl, C_2-6alkenyl and C_6-10aryl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a″, SR^a″, C(═
  
  O)R^b″, C(═
  
  O)NR^c″R^d″, C(═
  
  O)OR^a″, C(═
  
  S)NR^c″R^d″, OC(═
  
  O)R^b″, OC(═
  
  O)NR^c″R^d″, NR^c″R^d″, NR^c″C(O)R^b″, NR^c″C(═
  
  O)OR^a″, NR^c″S(═
  
  O)₂R^b″, S(═
  
  O)R^b″, S(═
  
  O)NR^c″R^d″, S(═
  
  O)₂OH, S(═
  
  O)₂R^b″, and S(═
  
  O)₂NR^c″R^d″;
  
  each R¹²is independently C_1-6alkyl, C_1-6alkoxy, halogen, trihalomethyl, —
  
  NR⁷R⁸, —
  
  OR⁹, —
  
  C(═
  
  O)R⁹, —
  
  C(═
  
  O)OR⁹, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^b, and S(═
  
  O)₂NR^cR^d, or —
  
  C(═
  
  O)NR⁷R⁸, wherein the C_1-6alkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, oxo, imino, guanidino, amidino, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═
  
  O)R^b, C(═
  
  O)NR^cR^d, C(═
  
  O)OR^a, C(═
  
  S)NR^cR^d, OC(═
  
  O)R^b, OC(═
  
  O)NR^cR^d, NR^cR^d, NR^cC(═
  
  O)R^b, NR^cC(═
  
  O)OR^a, NR^cS(═
  
  O)₂R^b, S(═
  
  O)R^b, S(═
  
  O)NR^cR^d, S(═
  
  O)₂OH, S(═
  
  O)₂R^b, and S(═
  
  O)₂NR^cR^d;
  
  R^a, R^a′ and R^a″ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocycloalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  
  R^b, R^b′ and R^b′ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  
  R^cand R^dare each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  
  or R^cand R^dtogether with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;
  
  R^c′ and R^d′ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  
  or R^c′ and R^d′ together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;
  
  R^c″ and R^d″ are each, independently, selected from H, C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl, wherein each of the C_1-6alkyl, C_1-6haloalkyl, C_2-6alkenyl, C_2-6alkynyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryl-C_1-6alkyl, cycloalkylalkyl and heterocyclylalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from OH, CN, NO₂, oxo, C_1-6alkoxy, amino, halo, C_1-6alkyl, C_1-6haloalkyl, C_1-6haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
  
  or R^c″ and R^d″ together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;
  
  m and n are each, independently, selected from 0, 1, 2 and 3; and
  
  each q is independently 0, 1 or 2.
- View Dependent Claims (2, 5, 9, 11, 14, 22, 24, 32, 36, 44, 46, 49, 53, 56, 57, 58, 59, 60, 61, 63, 65, 67, 75, 78, 79, 80, 82, 83, 84, 85, 88, 89, 91, 92, 94, 95, 97, 109, 110)
- - 2. The compound of claim 1, wherein R¹and R²are each, independently, selected from H, —
    - (CH₂)_mCH═
      
      CH(CH₂)_nR⁶, and C_1-6alkyl, wherein the C_1-6alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkoxy and C_1-6haloalkoxy.
  - 5. The compound of claim 1, wherein R¹and R²are each, independently, selected from H and C_1-4alkyl, wherein the C_1-4alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from OH and C_1-4alkoxy.
  - 9. The compound of claim 1, wherein R¹is methyl and R²is n-propyl.
  - 11. The compound of claim 1, wherein R³is C_1-6alkyl optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO₂, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, OR^a, SR^a, C(═
    - O)R^b, C(═
      
      O)NR^cR^d, C(═
      
      O)OR^a, C(═
      
      S)NR^cR^d, OC(═
      
      O)R^b, OC(═
      
      O)NR^cR^d, NR^cR^d, NR^cC(═
      
      O)R^b, NR^cC(═
      
      O)OR^a, NR^cS(═
      
      O)₂R^b, S(═
      
      O)R^b, S(═
      
      O)NR^cR^d, S(═
      
      O)₂OH, S(═
      
      O)₂R^b, and S(═
      
      O)₂NR^cR^d.
  - 14. The compound of claim 1, wherein R³is C_1-6alkyl optionally substituted by 1 or 2 OH.
  - 22. The compound of claim 1 wherein:
    - R⁴and R⁵are each, independently, selected from H, C_1-6alkyl, C_6-10aryl, —
      
      NR⁷R⁸, and —
      
      OR⁹, wherein each of the C_1-6alkyl and C_6-10aryl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryloxy, C_1-6alkoxy and C_1-6haloalkoxy;
      
      R⁷and R⁸are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl, C_6-10aryloxy-C_1-6alkyl;
      
      or R⁷and R⁸together with the N atom to which they are attached form a heterocyclyl group optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryloxy, C_1-6alkoxy and C_1-6haloalkoxy; and
      
      R⁹is C_1-6alkyl, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl, or C_6-10aryloxy-C_1-6alkyl.
  - 24. The compound of claim 1 wherein:
    - R⁴and R⁵are each, independently, selected from H, C_6-10aryl, azepanyl, morpholino, piperazinyl, piperidinyl, pyrrolidinyl, azetidinyl, aziridinyl, —
      
      NHR⁸, and —
      
      OR⁹; and
      
      R⁸and R⁹are each, independently, selected from C_1-6alkyl, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl.
  - 32. The compound of claim 1 wherein:
    - R¹is methyl;
      
      R²is n-propyl;
      
      R³is C_3-6alkyl optionally substituted by OH;
      
      one of R⁴and R⁵is H and the other is selected from C_6-10aryl, azepanyl, piperidinyl, pyrrolidinyl, azetidinyl, aziridinyl, —
      
      NHR⁸, and —
      
      OR⁹; and
      
      R⁸and R⁹are each, independently, C_1-6alkoxy-C_1-6alkyl.
  - 36. A compound of claim 1 wherein the compound is selected from the group consisting of:
44. The compound of claim 1 wherein R⁴and R⁵together with the two carbon atoms to which they are attached form a 5-7 membered cycloalkyl, a 5-7 membered heterocycloalkyl, or a 5-7 membered heteroaryl group, each optionally substituted by 1, 2,3, 4 or 5 R¹².
46. The compound of claim 1 wherein R⁴and R⁵together with the two carbon atoms to which they are attached form a 5-6 membered heteroaryl group optionally substituted by 1, 2 or 3 R¹².
49. The compound of claim 1 wherein:
- each R¹²is independently C_1-6alkyl, C_6-10aryl, heterocyclyl, —
  
  NR⁷R⁸, —
  
  OR⁹, —
  
  C(═
  
  O)R⁹, —
  
  C(═
  
  O)OR⁹, or —
  
  C(═
  
  O)NR⁷R⁸, wherein each of the C_1-6alkyl, C_6-10aryl and heterocyclyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryloxy, C_1-6alkoxy and C_1-6haloalkoxy;
  
  R⁷and R⁸are each, independently, selected from H, C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl, C_6-10aryloxy-C_1-6alkyl, wherein each of the C_1-6alkyl, C_1-6alkoxy, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryloxy, C_1-6alkoxy and C_1-6haloalkoxy;
  
  or R⁷and R⁸together with the N atom to which they are attached form a heterocyclyl group optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryloxy, C_1-6alkoxy and C_1-6haloalkoxy; and
  
  each R⁹is independently H or C_1-6alkyl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, OH, CN, NO₂, C_1-6alkyl, C_1-6haloalkyl, C_6-10aryl, C_3-14cycloalkyl, heterocyclyl, C_6-10aryloxy, C_1-6alkoxy and C_1-6haloalkoxy.
53. The compound of claim 1 wherein:
- each R¹²is independently C_6-10aryl, azepanyl, morpholino, piperazinyl, piperidinyl, pyrrolidinyl, azetidinyl, aziridinyl, —
  
  NHR⁸, or —
  
  OR⁹; and
  
  R⁸and R⁹are each, independently, selected from C_1-6alkyl, C_1-6alkoxy-C_1-6alkyl, C_6-10aryl, C_6-10aryl-C_1-6alkyl and C_6-10aryloxy-C_1-6alkyl.
56. The compound of claim 1 wherein each R¹²is independently phenyl, piperidinyl, —
- NHCH₂CH₂—
  
  OCH₃or —
  
  OCH₂CH₂—
  
  OCH₃.
57. A compound of claim 1 wherein the compound has Formula (II):
- or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer, wherein;
  
  one of D¹, D², D³and D⁴is N and the others are each independently CR¹³; and
  
  each R¹³is independently selected from H and R¹².
58. The compound of claim 57 wherein D¹is N.
59. The compound of claim 57 wherein D²is N.
60. The compound of claim 57 wherein D³is N.
61. The compound of claim 57 wherein D³is N.
63. The compound of claim 57 wherein at least two R¹³are H.
65. The compound of claim 57 wherein:
- R¹and R²are each, independently, selected from methyl, ethyl, n-propyl and n-butyl;
  
  R³is C_3-6alkyl optionally substituted by OH;
  
  each R¹²is independently C_6-10aryl, azepanyl, piperidinyl, piperazinyl, pyrrolidinyl, azetidinyl, aziridinyl, —
  
  NHR⁸, or —
  
  OR⁹; and
  
  R⁸and R⁹are each, independently, C_1-6alkoxy-C_1-6alkyl.
67. A compound of claim 57 wherein the compound is selected from the group consisting of:
- and the pharmaceutically acceptable salts thereof, tautomers thereof, and pharmaceutically acceptable salts of the tautomers.
75. A method of inducing an immune response in a subject, comprising:
- administering a compound of claim 1 to the subject in an amount sufficient to induce an immune response in the subject.
78. The method of claim 75, wherein the subject is suffering from a microbial infection.
79. The method of claim 75, wherein the subject is suffering from a viral infection.
80. The method of claim 79, wherein the viral infection is a viral infection caused by the hepatitis C virus (HCV) or by human immunodeficiency virus (HIV).
82. The method of claim 75, wherein the subject is suffering from abnormal cellular proliferation or cancer.
83. The method of claim 75, wherein the subject is suffering from allergic diseases.
84. The method of claim 75, wherein the subject is suffering from asthma.
85. The method of claim 75, wherein the subject is suffering from precancerous lesions, wherein the precancerous lesions are actinic keratosis.
88. The method of claim 75 wherein the compound is administered topically.
89. A pharmaceutical composition, comprising:
- the compound of claim 1 and a pharmaceutically acceptable excipient.
91. A method of enhancing the immune response to an antigen in a subject, comprising:
- administering to the subject a composition comprising a compound of claim 1 and an antigen, wherein the immune response to the antigen in the subject is enhanced.
92. A composition comprising the compound of claim 1 and an additional immunogenic composition or an antigen.
94. The composition of claim 92, further comprising an additional adjuvant.
95. The composition of claim 94 wherein the adjuvant is MF59.
97. The composition according to claim 92, wherein the antigen is a bacterial antigen or a viral antigen.
109. The composition according to claim 97, wherein the antigen is a viral antigen from a virus selected from the group consisting of Hepatitis C virus, Human Immunodeficiency virus, Hepatitis B virus, Human Papilloma virus and Influenza virus.
110. The composition according to claim 97, wherein the antigen is an influenza antigen.

3-4. -4. (canceled)

6-8. -8. (canceled)

10. (canceled)

12-13. -13. (canceled)

15-21. -21. (canceled)

23. (canceled)

25-31. -31. (canceled)

33-35. -35. (canceled)

37-43. -43. (canceled)

45. (canceled)

47-48. -48. (canceled)

50-52. -52. (canceled)

54-55. -55. (canceled)

62. (canceled)

64. (canceled)

66. (canceled)

68-73. -73. (canceled)

76-77. -77. (canceled)

81. (canceled)

86-87. -87. (canceled)

90. (canceled)

93. (canceled)

96. (canceled)

98-108. -108. (canceled)

111-114. -114. (canceled)

115. An immunogenic composition comprising an antigen and an imidazo[1,2-a]quinoxalin-4-amine effective to stimulate a cell mediated response to said antigen.

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Novartis Ag
Original Assignee
Novartis Ag
Inventors
Sutton, James, Valiante, Nicholas

Granted Patent

US 8,063,063 B2
Time in Patent Office

Days
Field of Search
US Class Current

424/209.100
CPC Class Codes

A61P 31/04   Antibacterial agents

A61P 31/12   Antivirals

C07D 471/04   Ortho-condensed systems

C07D 471/14   Ortho-condensed systems

IMMUNOPOTENTIATING COMPOUNDS

First Claim

2 Assignments

0 Petitions

Accused Products

Abstract

Citations

115 Claims

Specification

Solutions

Use Cases

Quick Links

IMMUNOPOTENTIATING COMPOUNDS

First Claim

2 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

Citations

115 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links